JMD ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

A more recent version of this article appeared on July 1, 2008

Published online before print June 13, 2008
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
jmoldx.2008.080062v1
10/4/301    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Zhang, L.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, L.
Related Collections
Right arrowRelated Article
Copyright © 2008 American Society for Investigative Pathology
Journal of Molecular Diagnostics, doi:10.2353/jmoldx.2008.080062


Accepted for publication April 28, 2008.


Article

Immunohistochemistry versus Microsatellite Instability Testing for Screening Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome. Part II. The Utility of Microsatellite Instability Testing

Liying Zhang@

From the Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York

@ To whom correspondence should be addressed. E-mail: zhangl2{at}mskcc.org.


   Abstract

Germline mutations in the mismatch repair genes mutL homolog 1 (MLH1) and mutS homolog 2 (MSH2), MSH6, and postmeiotic segregation increased 2 (PMS2) lead to the development of hereditary nonpolyposis colorectal cancer (HNPCC). Diagnosis of HNPCC relies on the compilation of a thorough family history of cancer, documentation of pathological findings, tumor testing for microsatellite instability (MSI) and immunohistochemistry (IHC), and germline mutation analysis of the suspected genes. As a hallmark of HNPCC, microsatellite instability is widely accepted as a primary method for identifying individuals at risk for HNPCC. It serves as an excellent, easy-to-evaluate marker of mismatch repair deficiency. Recent improvements in MSI testing have significantly enhanced the accuracy and reduced its cost. Proficiency testing for MSI is available, and laboratory-to-laboratory reproducibility of such testing can be easily evaluated. In addition, the combination of microsatellite instability testing, MLH1 promoter methylation analysis, and BRAF (V600E) mutation analysis can distinguish a sporadic colorectal cancer from one associated with HNPCC, helping to avoid costly molecular genetic testing for germline mutations in mismatch repair genes. In this article, we discuss the development of MSI markers used for HNPCC screening and focus on the advantages and disadvantages of MSI testing in screening for HNPCC patients. We conclude that MSI is as sensitive and specific as IHC, given its excellent reproducibility and its potential capability to indicate mutations not be detected by IHC. MSI has been used and will continue to prevail as the primary screening tool for identifying HNPCC patients.


Related Article

Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome: Part I. The Utility of Immunohistochemistry
Jinru Shia
J. Mol. Diagn. 2008 10: 293-300. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
W. He, Y. Zhao, C. Zhang, L. An, Z. Hu, Y. Liu, L. Han, L. Bi, Z. Xie, P. Xue, et al.
Rad9 plays an important role in DNA mismatch repair through physical interaction with MLH1
Nucleic Acids Res., November 1, 2008; 36(20): 6406 - 6417.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2008 by the American Society for Investigative Pathology and the Association for Molecular Pathology.